Navigation Links
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
Date:10/31/2013

ENMD-2076 in this difficult to treat patient population.  We look forward to working closely with EntreMed and colleagues from other sites in this Phase 2 trial."

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer commented, "We are very pleased to have Dr. Oza lead this trial.  Dr. Oza was a principal investigator in our Phase 2 study in platinum resistant ovarian cancer and has been instrumental in advancing our development program targeting this indication.  The cumulative evidence has indicated the potential effectiveness of a combined anti-angiogenic and anti-Aurora A targeted approach in OCCC, and we believe ENMD-2076 presents strong clinical and scientific rationale for the treatment of this subset of patient population.  This trial will provide us with more insight into the drug's clinical activities and its correlation with biomarkers."

Dr. Ren further commented, "Together with our trials in triple negative breast cancer and soft tissue sarcoma, this is the third clinical trial we have initiated for ENMD-2076 under our US/China development model.  We intend to expand the trial into China once we have it underway in Canada and the US.  Our goal is to reach a clinical inflection point using a cost-effective approach that combines speed, quality and lower costs, in order to maximize the value proposition of ENMD-2076. We are confident that we will reach this goal."

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Second Quarter 2013 Financial Results
2. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
3. EntreMed Reports First Quarter 2013 Financial Results
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
10. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
11. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CITY, Calif., Aug. 3, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... business update and reported financial results for the three ... Business highlights include: , On July 23, 2015, ... adopted a positive opinion for Zalviso™ for the management ...
(Date:8/3/2015)... -- Your doctor has recommended surgery for your foot ... possible outcome. Your orthopaedic foot and ankle specialist is ... a three-part online series to help you ... Orthopaedic Foot & Ankle Society (AOFAS) both before ... heal as quickly as possible. For example, ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 Par ... a conference call on Friday, August 7, 2015 at ... for the second quarter ended June 30, 2015.  Par ... available to the public in its filings with the ... information available on its website by following the instructions ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Patient Guide: How to Prepare for Surgery 2
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... label design, product packaging, and fulfillment services, joined over 200 other Long Island-based ... was held on Tuesday, July 28th at Jones Beach State Park in Wantagh, ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... patients whose cancer has come back: Retreatment may be a viable option. Surviving ... read it now. , According to surgeons at the University of New ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and other long-term care facilities, today announced details of the Advanced level of ... and centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is ...
(Date:8/4/2015)... ... 04, 2015 , ... A new report by The 2112 ... will grow at least 6 percent in 2015, as solution providers expand sales, ... their OEM/vendor partners. , The 2112 Group’s 2015 Midyear Channel Performance Report ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3
... developing clothing, which they say will be able to monitor ... sensors designed to monitor body fluids such as blood and ... use the clothes to check on groups such as recovering ... ,As of now, the Biotex programme, which is ...
... of psychologists from Durham University and two Polish institutions ... their fathers are more likely to select partners ... negative or less positive relationships were not attracted to ... ,Due to be published in the July issue of ...
... total economic shutdown as some 2 million public servants ... 'It's going to be a total shutdown tomorrow in public ... involving marches in major cities and pickets outside government buildings,' ... Trade Unions (COSATU) labor federation had warned Tuesday. ...
... (CNBG) led by Madam Wang Lifeng, President and CEO ... Union Minister for Health & Family Welfare , Dr. ... CNBG is Government owned, the largest vaccine manufacturer and ... discussed the supply live of JE vaccine in order ...
... than leave you short-tempered: it can also stress your ... death, according to a study released Wednesday . ... sleep loss have been well-documented, ranging from lowered concentration ... by researchers at the University of Pennsylvania School of ...
... both houses of the Legislature are on the brink of ... the Assembly's bill is Manhattan Assemblyman Richard Gottfried , who ... serious medical conditions who could have a better quality and ... a person would have to have a debilitating or life-threatening ...
Cached Medicine News:Health News:Scientists Developing 'intelligent Clothes' to Monitor Wearer's Health 2Health News:Women Choose Their Men With Their Fathers Resemblance 2Health News:South Africa Facing Major Economic Shutdown as Health Workers are Sacked En Masse 2Health News:Chinese Delegation Meets Health Minister Regarding Japanese Encephalitis Vaccine Supply 2Health News:Insufficient Sleep Increases Risk of Cardiovascular Disease: Study 2Health News:Medical Marijuana to Be Legalized 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: